Evidence map›Paper›PMID 41705898›Full record

ArticleEBioMedicine2025

Imaging brain development in a KCNQ2-developmental and epileptic encephalopathy mouse model: identifying early biomarkers for functional and structural brain changes.

Charissa Millevert, Nicholas Vidas-Guscic, Mohit H Adhikari, Alan Miranda, Liesbeth Vanherp, Laurent Villard, Elisabeth Jonckers, Philippe Joye, Johan Van Audekerke, Ignace Van Spilbeeck and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Charissa MillevertVIB Center for Molecular Neurology, VIB, 2610, Antwerp, Belgium; Dept. of Neurology, University Hospital, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Nicholas Vidas-GuscicBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Mohit H AdhikariBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Alan MirandaMolecular Imaging Center Antwerp (MICA), University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Liesbeth VanherpμNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Laurent VillardAix Marseille Univ, Inserm, MMG, U1251, Marseille, France; Service de Génétique Médicale, AP-HM, Hôpital de La Timone, Marseille, France.
Elisabeth JonckersBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Philippe JoyeMolecular Imaging Center Antwerp (MICA), University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Johan Van AudekerkeBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Ignace Van SpilbeeckBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Els De VriendtVIB Center for Molecular Neurology, VIB, 2610, Antwerp, Belgium.
Marleen VerhoyeBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Steven StaelensMolecular Imaging Center Antwerp (MICA), University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Daniele BertoglioBio-Imaging Lab, University of Antwerp, 2610, Antwerp, Belgium; Molecular Imaging Center Antwerp (MICA), University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium.
Sarah WeckhuysenVIB Center for Molecular Neurology, VIB, 2610, Antwerp, Belgium; Dept. of Neurology, University Hospital, 2610, Antwerp, Belgium; Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, 2610, Antwerp, Belgium; μNEURO Research Centre of Excellence, University of Antwerp, 2610, Antwerp, Belgium. Electronic address: Sarah.Weckhuysen@uantwerpen.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKCNQ2-developmental and epileptic encephalopathy (KCNQ2-DEE) is a severe neurodevelopmental disorder (NDD) characterised by early-life seizures but persistent cognitive impairment. The absence of early, quantifiable preclinical biomarkers for neurodevelopmental dysfunction limits the evaluation of new treatments. We hypothesise that key brain maturation processes are altered early in disease development and could serve as biomarkers for neurodevelopmental dysfunction.

methodsWe performed longitudinal in-vivo brain imaging in 37 kcnq2

findingsAt infant age, KI mice showed increased FC relative to WT, particularly within the default mode-like network (DMLN). During the juvenile stage, KI mice exhibited modest elevated synaptic density across brain regions, most notably in the cerebellum. By adulthood, KI mice displayed reduced FC, especially within the DMLN, compared to WT. No significant microstructural genotype-by-age interactions were found.

interpretationKCNQ2-DEE disrupts neurodevelopment, with early hyperconnectivity and delayed synaptic pruning transitioning to adult hypoconnectivity. While this pattern is too subtle to use as a standalone biomarker, these findings establish a foundation for their use in longitudinal preclinical research targeting early therapeutic intervention.

fundingSupported by the University of Antwerp, Fonds Wetenschappelijk Onderzoek, the Queen Elisabeth Medical Foundation, the European Joint Programme on Rare Disease, and Fondation Lejeune.

Indexed as

BrainEpilepsyKCNQ2 Potassium ChannelAnimalsBiomarkersDiffusion Tensor ImagingDisease Models, AnimalHumansMagnetic Resonance ImagingMaleMiceNeurodevelopmentPositron-Emission TomographyBiomarkersKCNQ2 Potassium ChannelDiffusion tensor imagingKCNQ2Neurodevelopmental disordersPositron emission tomographyResting-state functional magnetic resonance imaging

Identifiers

PMID41705898
PMCPMC12595386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.